CICC: Maintain outperform rating on WuXi Biologics (02269.HK) with a target price of HK$48.

Zhixin Finance and Economics App learned that CICC released a research report stating that it maintains a outperform rating for WuXi Biologics (02269.HK) and keeps its profit forecast and target price unchanged, maintaining a target price of 48 Hong Kong dollars (upside potential of 44.0%), corresponding to a P/E ratio of 27.8x/23.7x for 26/27 years adjusted earnings, while the current stock price corresponds to a P/E ratio of 19.3x/16.5x for 26/27 years adjusted earnings.